

## Gene Section

### Mini Review

# RB1 (retinoblastoma)

Dietmar R Lohmann

Institut fuer Humangenetik, Hufelandstr. 55, D-45122 Essen, Germany (DRL)

Published in Atlas Database: September 1999

Online updated version : <http://AtlasGeneticsOncology.org/Genes/RB1ID90.html>

DOI: 10.4267/2042/37533

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## Identity

**Other names:** human retinoblastoma susceptibility gene


**HGNC (Hugo) :** RB1

**Location :** 13q14

## DNA/RNA

### Description

27 exons spanning 180 kb.



c-RB1 at 13q14 in normal cells: PAC 825K22 (top) and PAC 971H14 (bottom) - Courtesy Mariano Rocchi.

### Transcription

4.7 kb mRNA, 2.7 kb open reading frame, 2 kb 3'-UTR.

## Protein

### Description

928 aa nuclear phosphoprotein; 110 kDa; pRB is phosphorylated by members of the cyclin-dependent kinase (cdk) system prior to the entry into S-phase; hypophosphorylated pRB binds to members of the E2F family of transcription factors; binding to E2F is

mediated by by two domains within pRB (pocket domains).

### Expression

Ubiquitous.

### Localisation

Nucleus.

### Function

Cell cycle regulation, differentiation.

### Homology

pRB, p107, and p130 constitute a small family of nuclear proteins with significant sequence similarity in two discontinuous areas (pockets domains); conditional on the phosphorylation status, these pocket proteins can bind transforming proteins of DNA tumor viruses as well as nuclear proteins.

## Mutations

### Germinal

Germline mutations in the RB1 gene are causative for hereditary predisposition to retinoblastoma; the spectrum of predisposing mutations includes large deletions (about 20%), single base substitutions (about 50%) and small length mutations (about 30%); most mutations are associated with almost complete penetrance: some rare alleles show incomplete penetrance and reduced expressivity (low penetrance retinoblastoma).

### Somatic

In retinoblastomas, both RB1 alleles are mutated; in addition to the mutational spectrum of germinal mutations, retinoblastomas can show loss of heterozygosity and hypermethylation at the CpG-island associated with the 5' end of the RB1 gene.

## Implicated in

### **Retinoblastoma**

#### **Disease**

Hereditary predisposition to retinoblastoma formation in carriers of a germinal mutation. Somatic inactivation of both RB1 alleles can result in sporadic unilateral retinoblastoma.

### **Sarcomas**

#### **Disease**

Carriers of a germinal RB1 gene mutation are predisposed to soft tissue sarcomas and osteogenic sarcomas. Somatic inactivation of both RB1 alleles observed in some sarcomas

### **Various cancers**

#### **Disease**

RB1 gene mutations have been observed in several tumor entities. In lung cancer there is a notable high frequency of RB1 gene mutations although no increased incidence of these tumors has been observed in carriers of a germinal RB1 gene mutation.

## References

T'Ang A, Wu KJ, Hashimoto T, Liu WY, Takahashi R, Shi XH, Mihara K, Zhang FH, Chen YY, Du C. Genomic organization of the human retinoblastoma gene. *Oncogene*. 1989 Apr;4(4):401-7

Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. *EMBO J*. 1991 Dec;10(13):4279-90

Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. *Genes Dev*. 1992 Feb;6(2):177-85

Toguchida J, McGee TL, Paterson JC, Eagle JR, Tucker S, Yandell DW, Dryja TP. Complete genomic sequence of the human retinoblastoma susceptibility gene. *Genomics*. 1993 Sep;17(3):535-43

Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell*. 1995 May 5;81(3):323-30

Taya Y. RB kinases and RB-binding proteins: new points of view. *Trends Biochem Sci*. 1997 Jan;22(1):14-7

---

*This article should be referenced as such:*

Lohmann DR. RB1 (retinoblastoma). *Atlas Genet Cytogenet Oncol Haematol*. 1999; 3(3):137-138.

---